Literature DB >> 10350396

Early switch from intravenous to oral antibiotics: guidelines and implementation in a large teaching hospital.

F Sevinç1, J M Prins, R P Koopmans, P N Langendijk, P M Bossuyt, J Dankert, P Speelman.   

Abstract

In recent years 'switch therapy' has been advocated: short intravenous antibiotic therapy, for 2-3 days, followed by oral treatment for the remainder of the course. Little is known about the number of patients that could benefit from early switch therapy and the consequences of introducing this strategy in everyday practice. We prospectively registered all antibiotic courses on wards for Internal Medicine, Surgery, and Pulmonology during a 2 month period, before (n = 362, inventorial phase) and after (n = 281, implementation phase) the introduction of guidelines for switching therapy. Approximately 40% of all patients who started on iv antibiotics were candidates for an early iv-oral switch. During the inventorial phase, 54% (52/97) of eligible patients were switched to oral treatment, after a median of 6 days (range 2-28 days). After implementation of the guidelines, this percentage rose to 83% (66/80) (difference 29%, 95% CI 16-42%; P < 0.001). Therapy was also switched earlier, after a median of 4 days (range 2 to 16 days). In the 6 weeks after completion of the oral course, recurrence of infections, or readmissions due to reinfections did not occur. Compared with the inventorial phase, 43% of iv administrations could be avoided, that is >6000 per year. This means a potential annual reduction of dfl.60,000 (c. US$30,000) of administration costs. The potential savings in purchase costs of the antibiotics were dfl.54,000 (US$27,000) annually. In conclusion, a substantial number of patients starting on iv antibiotics were candidates for an early iv-oral switch. The guidelines were well accepted by the physicians and substantial savings in costs and nursing time were achieved.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10350396     DOI: 10.1093/jac/43.4.601

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  45 in total

1.  Pharmacokinetics of a new, orally available ceftriaxone formulation in physical complexation with a cationic analogue of bile acid in rats.

Authors:  Seulki Lee; Sang Kyoon Kim; Dong Yun Lee; Su Young Chae; Youngro Byun
Journal:  Antimicrob Agents Chemother       Date:  2006-05       Impact factor: 5.191

2.  Clinical pharmacy and pediatrics: why focus on antibiotics?

Authors:  T G M Bauters; B T Nguyen; F Buyle; P Schelstraete; P De Cock; A De Jaeger; A Verrijckt; H Robays
Journal:  Pharm World Sci       Date:  2006-06-04

3.  CANVAS 1 and 2: analysis of clinical response at day 3 in two phase 3 trials of ceftaroline fosamil versus vancomycin plus aztreonam in treatment of acute bacterial skin and skin structure infections.

Authors:  H David Friedland; Tanya O'Neal; Donald Biek; Paul B Eckburg; Douglas R Rank; Lily Llorens; Alex Smith; Gary W Witherell; Joseph B Laudano; Dirk Thye
Journal:  Antimicrob Agents Chemother       Date:  2012-02-06       Impact factor: 5.191

4.  Doctors and medical training.

Authors:  Moyez Jiwa
Journal:  Australas Med J       Date:  2012-09-30

5.  Implementing an Antibiotic Stewardship Program: Guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America.

Authors:  Tamar F Barlam; Sara E Cosgrove; Lilian M Abbo; Conan MacDougall; Audrey N Schuetz; Edward J Septimus; Arjun Srinivasan; Timothy H Dellit; Yngve T Falck-Ytter; Neil O Fishman; Cindy W Hamilton; Timothy C Jenkins; Pamela A Lipsett; Preeti N Malani; Larissa S May; Gregory J Moran; Melinda M Neuhauser; Jason G Newland; Christopher A Ohl; Matthew H Samore; Susan K Seo; Kavita K Trivedi
Journal:  Clin Infect Dis       Date:  2016-04-13       Impact factor: 9.079

6.  Implementation of guidelines for sequential therapy with fluoroquinolones in a Belgian hospital.

Authors:  Franky Buyle; Dirk Vogelaers; Renaat Peleman; Georges Van Maele; Hugo Robays
Journal:  Pharm World Sci       Date:  2010-04-01

7.  Impact of switching from intravenous to oral linezolid therapy in Japanese patients: a retrospective cohort study.

Authors:  Akihiro Tanaka; Akiko Yano; Shinichi Watanabe; Mamoru Tanaka; Hiroaki Araki
Journal:  J Pharm Policy Pract       Date:  2016-10-28

Review 8.  Cost-effective approaches to the treatment of community-acquired pneumonia in the era of resistance.

Authors:  Joseph L Kuti; Blair Capitano; David P Nicolau
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

9.  Hospital pharmacists' reinforcement of guidelines for switching from parenteral to oral antibiotics: a pilot study.

Authors:  Vera von Gunten; Viviane Amos; Anne-Laure Sidler; Johnny Beney; Nicolas Troillet; Jean-Philippe Reymond
Journal:  Pharm World Sci       Date:  2003-04

10.  Outcomes of early switching from intravenous to oral antibiotics on medical wards.

Authors:  Dominik Mertz; Michael Koller; Patricia Haller; Markus L Lampert; Herbert Plagge; Balthasar Hug; Gian Koch; Manuel Battegay; Ursula Flückiger; Stefano Bassetti
Journal:  J Antimicrob Chemother       Date:  2009-04-28       Impact factor: 5.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.